Vir Biotechnology Announces Appointment of Suzanne Topalian to its Board of Directors
Key Highlights
- ➤Vir Biotechnology appoints Suzanne Topalian to its Board, effective October 27, 2026
- ➤Topalian brings cancer immunotherapy expertise as Vir builds its oncology portfolio
- ➤Vir is developing masked T-cell engagers targeting solid tumors through its PRO-XTEN platform
Expert Statements
Marianne De Backer, President and Chief Executive Officer of Vir Biotechnology
“Suzanne brings extraordinary depth of expertise in cancer immunotherapy and a track record of advancing groundbreaking science into meaningful solutions for patients.”
Marianne De Backer, President and Chief Executive Officer of Vir Biotechnology
“Her perspective will be tremendously valuable as we continue to build our oncology portfolio and apply our integrated discovery and engineering capabilities with the broad potential of the PRO-XTEN(®) platform to develop new therapeutic approaches for patients with cancer.”
Suzanne Topalian, Bloomberg-Kimmel Professor of Cancer Immunotherapy at the Johns Hopkins University School of Medicine
“Vir Biotechnology is building a differentiated scientific foundation in oncology, bringing together impressive capabilities in the development of masked T-cell engagers that could unlock the potential of this powerful modality for solid tumors.”
Suzanne Topalian, Bloomberg-Kimmel Professor of Cancer Immunotherapy at the Johns Hopkins University School of Medicine
“I’m excited to join the Board and contribute to the accelerating momentum of the company’s clinical and strategic progress.”
Vir Biotechnology Announces Appointment of Suzanne Topalian to its Board of Directors
Vir Biotechnology, Inc. (Nasdaq: VIR), today announced the appointment of Suzanne Topalian, M.D., to its Board of Directors, effective October 27, 2026. Dr. Topalian is the Bloomberg-Kimmel Professor of Cancer Immunotherapy at the Johns Hopkins University School of Medicine* and serves as Associate Director of the Bloomberg-Kimmel Institute for Cancer Immunotherapy and Director Melanoma/Skin Cancer Program in the Kimmel Cancer Center at Johns Hopkins.
Get started
Create a free account to read the full story.